GLSI4:30 PMGreenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filinggreenwichlifesciences.com
GLSI6:00 AMGreenwich LifeSciences Provides Update Regarding Form 10-K FilingInterim Data • Phase 3greenwichlifesciences.com
GLSI6:00 AMGreenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026Presentation / Abstract • Phase 3greenwichlifesciences.com
GLSI5:00 PMGreenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filinggreenwichlifesciences.com
GLSI6:00 AMGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026Presentation / Abstract • Phase 3greenwichlifesciences.com
GLSI6:00 AMGreenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potentialgreenwichlifesciences.com
GLSI6:00 AMGreenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01greenwichlifesciences.com
GLSI6:00 AMGreenwich LifeSciences Provides Update on Upcoming AACR MeetingPresentation / Abstract • Phase 3greenwichlifesciences.com
GLSI6:00 AMGreenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01Interim Data • Phase 3greenwichlifesciences.com
GLSI6:00 AMGreenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01greenwichlifesciences.com
GLSI6:00 AMGreenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01greenwichlifesciences.com